An interventional study of GPT-QPL in Lymphoma and Multiple Myeloma, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Health services research
Among 10 studies in Lymphoma by Washington University School of Medicine — 1 open to participants now, 2 under way, none of them phase 3. Lymphoma · Washington University School of Medicine.
Among the 10 studies in Lymphoma by Washington University School of Medicine, this one is the 5th largest by planned enrollment, is the only one that started in 2025, is one of 4 with no phase, and was the 10th registered.
3,018 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
This study's planned enrollment of 40 is close to the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →1 of the 10 studies in Lymphoma by Washington University School of Medicine is open now, in 1 country. Each count lists the studies.
Of the 347 Lymphoma studies recruiting now, 227 (65%) set no upper age limit and 79 (23%) stop at 75 or younger; 78 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →10 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2025.
Median enrollment 37 across the 10 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
Washington University School of Medicine is the lead sponsor of 1,803 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
1 of the studies in Lymphoma by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226934Washington University School of MedicineAn AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers | 2026-12-31 |
Among the 10 studies in Lymphoma by Washington University School of Medicine, from their registry updates:
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore patterns in questions generated by WashU ChatGPT. Patients will also provide feedback pertaining to the perceived helpfulness and ease-of-use of WashU-ChatGPT-generated question lists, as well as their attitudes and intentions regarding use of AI chatbots and whether they would engage in pre-appointment AI-assisted question brainstorming independently in the future.
Eligibility Criteria as determined by Electronic Health Record (EHR) Screening:
Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include:
Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks.
Eligibility Criteria as determined by subsequent recruitment phone call or In-person approach after a clinic appointment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will complete surveys at appointment 1 (pre-intervention) and after being provided the AI-Generated, Personalized Question Prompt List at appointment 2 (post-intervention).
Other: GPT-QPL
A research team member will generate a QPL that is personalized to the patient's demographics (from EHR screening and Baseline Demographic Survey) and concerns (from Distress Thermometer Problem Checklist and Interview).
Also known as: AI-Generated, Personalized Question Prompt List
Changes in communicative self-efficacy
* Communicative self-efficacy is measured by Self-efficacy survey . * Dependent samples t-tests will be used to assess within-subject changes. * The Self-Efficacy survey consists of two scales containing 10 questions each, with answers ranging from 1=not successful to 5=very successful or 1=not confident to 5=very confident. The total score on each scale ranges from 10-50 with a higher score on Scale 1 (the PEPPI-5) representing higher self-efficacy related to communicating with physicians in general and a higher score on Scale 2 (researcher-designed questions based on Social Cognitive Theory) representing higher self-perceived success at communication with the physician during the immediately preceding appointment.
Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)
Changes in perceived amount of cancer information received as measured by an abbreviated version the EORTC QLQ - INFO25
* Dependent samples t-tests will be used to assess within-subject changes. * The abbreviated version of the EORTC QLQ-INFO 25 being used for this outcome consists of three scales containing a total of 13 questions ranging from 1=not at all to 4=very much. Raw scores are converted using linear transformations. The total score range for each scale is 0-100. A higher score on Scale 1 represents a higher perceived degree of information received about cancer diagnosis, a higher score on Scale 2 represents a higher perceived degree of information received about medical tests, and a higher score on Scale 3 represents a higher perceived degree of information received about cancer treatment.
Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)
Changes in satisfaction with cancer information received as measured by the EORTC QLQ - INFO25
* Dependent samples t-tests will be used to assess within-subject changes. * An additional single item scale from the EORTC QLQ - INFO 25 will be used to measure satisfaction with cancer information received. The answer ranges from 1=not at all to 4=very much. The raw score is converted using the same linear transformation as other EORTC QLQ-INFO 25 scales. The total score range is 0-100, and a higher score represents higher satisfaction with cancer information received.
Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)
Changes in the number of questions asked during appointments
* Number of questions asked is measured by audio recordings of the clinic appointments. * Dependent samples t-tests will be used to assess within-subject changes.
Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)
Changes in self-reported degree of intention to use AI chatbots for healthcare tasks
* Self-reported degree of intention is measured by one-item AI Chatbot Use survey consisting of a 7-point Likert Scale question asking how frequently participants intend to use AI chatbots for healthcare tasks within the next month. The answer ranges from 1=Never to 7=Several times a day. The total score range is 1-7, and a higher score represents more frequent intended use of AI chatbots for healthcare tasks. * Dependent samples t-tests will be used to assess within-subject changes.
Time frame: Appointment 1 (pre-intervention) and appointment 2 (post-intervention) (estimated to be 12 weeks)
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →